Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck

This page shows the latest Lundbeck news and features for those working in and with pharma, biotech and healthcare.

Lundbeck’s key products shine in Q2 but problems remain

Lundbeck’s key products shine in Q2 but problems remain

Sales of the four key products accounted for more than half of Lundbeck’s sales in the quarter. ... Following the Abide Therapeutics acquisition in 2Q19, Lundbeck's total deal capacity is around $4bn-5bn.

Latest news

More from news
Approximately 51 fully matching, plus 113 partially matching documents found.

Latest Intelligence

  • Digital disruption Digital disruption

    R&D, this time within psychiatric and neurological treatments, was in the mind of Lundbeck executives when they signed a drug research deal with IBM Watson Health in February. ... Starting with projects in schizophrenia and Parkinson’s disease,

  • Communiqué Awards 2014 Digital Publication Communiqué Awards 2014 Digital Publication

    See which healthcare communications programmes made a real difference to health outcomes with the Communiqué Awards digital publication.

  • The Chinese diabetes challenge The Chinese diabetes challenge

    Last month's ChinaBio Partnering Forum in Suzhou, for example, was sponsored by (among others) AstraZeneca, Bayer, Bristol-Myers Squibb, Johnson &Johnson, Lilly, Lundbeck, Novo Nordisk and Roche.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    825. Chelsea Therapeutics/ Lundbeck. Company acquisition. Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved).

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    1, 030. Chelsea / Lundbeck. Company acquisition. US company with treatments for rare neurologic diseases.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 20 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics